GlassScriptPhysician profile
Melissa B Jackson
NPI 1427562156
$7,750.59
in general payments reported to CMS, 2019-2025
36 companies · $39.34 in 2025
The $39.34 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,204 · 2022: $4,304 · 2023: $956 · 2024: $247 · 2025: $39.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,721.69 | 2022 | |
| Abbvie INC. | $1,059.17 | 2021-2024 | |
| Avanir Pharmaceuticals, INC. | $585.68 | 2021-2022 | |
| Si-Bone, INC. | $545.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $370.79 | 2021-2025 | Ajovy, Austedo Xr, Austedo |
| Amgen INC. | $346.23 | 2021-2023 | Aimovig |
| Allergan, INC. | $291.46 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $277.05 | 2022 | |
| Pfizer INC. | $272.43 | 2023 | |
| Eisai INC. | $266.93 | 2021-2022 | |
| Sk Life Science, INC. | $221.59 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $176.78 | 2023-2024 | |
| Genzyme Corporation | $160.96 | 2021-2023 | |
| Kyowa Kirin, INC. | $144.80 | 2021-2023 | Nourianz |
| Lundbeck LLC | $129.59 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $125.81 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $120.72 | 2021-2023 | Nuplazid |
| Csl Behring | $115.38 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $115.00 | 2021 | |
| Mdd US Operations, LLC | $97.32 | 2022-2023 | Xadago, Apokyn |
| Emd Serono, INC. | $81.10 | 2021-2023 | Mavenclad |
| Otsuka America Pharmaceutical, INC. | $73.39 | 2023-2024 | Nuedexta |
| Lilly USA, LLC | $72.99 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $62.05 | 2023 | Ultomiris |
| Janssen Pharmaceuticals, INC | $44.21 | 2022-2023 | Ponvory |
| Sunovion Pharmaceuticals INC. | $43.30 | 2021 | |
| Argenx US, INC. | $41.21 | 2022 | |
| Biogen, INC. | $32.65 | 2023 | Tysabri, Vumerity |
| Sumitomo Pharma America, INC. | $30.62 | 2023 | Aptiom |
| Genentech USA, INC. | $25.76 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $21.78 | 2023 | Relyvrio |
| Ambu INC. | $17.91 | 2023 | |
| Sanofi-Aventis U.S. LLC | $16.92 | 2021 | |
| Neurelis, INC. | $16.28 | 2023 | Valtoco |
| Horizon Therapeutics Plc | $13.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.